{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T02:43:09Z","timestamp":1768617789849,"version":"3.49.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1124\/dmd.117.078972","type":"journal-article","created":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T16:15:39Z","timestamp":1519402539000},"page":"740-748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Physiologically Based Pharmacokinetic Modeling of Bosentan Identifies the Saturable Hepatic Uptake As a Major Contributor to Its Nonlinear Pharmacokinetics"],"prefix":"10.1016","volume":"46","author":[{"given":"Masanobu","family":"Sato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Toshimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuko","family":"Tomaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Yoshikado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Hisaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wooin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.117.078972_bib1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1046\/j.1523-1755.2000.00838.x","article-title":"Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A","volume":"57","author":"Binet","year":"2000","journal-title":"Kidney Int"},{"key":"10.1124\/dmd.117.078972_bib2","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1124\/dmd.114.060244","article-title":"Effects of cytochrome P450 2C9 polymorphism on bosentan metabolism","volume":"42","author":"Chen","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.078972_bib3","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.117.078972_bib43","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/00003088-200342030-00004","article-title":"Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin","volume":"42","author":"Dingemanse","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.117.078972_bib4","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2165\/00003088-200443150-00003","article-title":"Clinical pharmacology of bosentan, a dual endothelin receptor antagonist","volume":"43","author":"Dingemanse","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.117.078972_bib5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/bph.12126","article-title":"Phase I and II metabolism and MRP2-mediated export of bosentan in a MDCKII-OATP1B1-CYP3A4-UGT1A1-MRP2 quadruple-transfected cell line","volume":"169","author":"Fahrmayr","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1124\/dmd.117.078972_bib6","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2174\/138920010794328931","article-title":"PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism","volume":"11","author":"Fan","year":"2010","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.117.078972_bib7","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","article-title":"Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial","volume":"371","author":"Gali\u00e8","year":"2008","journal-title":"Lancet"},{"key":"10.1124\/dmd.117.078972_bib8","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1124\/dmd.105.007658","article-title":"Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement","volume":"34","author":"Hallifax","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.078972_bib9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1023\/A:1023294632129","article-title":"Analysis of nonlinear and nonsteady state hepatic extraction with the dispersion model using the finite difference method","volume":"26","author":"Hisaka","year":"1998","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/dmd.117.078972_bib10","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1208\/s12248-016-9992-0","article-title":"Pharmacokinetic modeling and Monte Carlo simulation to predict interindividual variability in human exposure to oseltamivir and its active metabolite, Ro 64-0802","volume":"19","author":"Ito","year":"2017","journal-title":"AAPS J"},{"key":"10.1124\/dmd.117.078972_bib12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1124\/dmd.114.059105","article-title":"Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions","volume":"43","author":"Izumi","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.078972_bib14","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1124\/dmd.111.042994","article-title":"Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data","volume":"40","author":"Jones","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.078972_bib15","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2133\/dmpk.DMPK-09-RG-038","article-title":"Prediction of interindividual variability in pharmacokinetics for CYP3A4 substrates in humans","volume":"25","author":"Kato","year":"2010","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.117.078972_bib16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2133\/dmpk.18.121","article-title":"Evaluation of methods for predicting drug-drug interactions by Monte Carlo simulation","volume":"18","author":"Kato","year":"2003","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.117.078972_bib17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2133\/dmpk.24.37","article-title":"In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney","volume":"24","author":"Kusuhara","year":"2009","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.117.078972_bib18","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1124\/dmd.117.078790","article-title":"A study on pharmacokinetics of bosentan with systems modeling, part 1: translating systemic plasma concentration to liver exposure in healthy subjects","volume":"46","author":"Li","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.078972_bib19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/bcp.12177","article-title":"Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers","volume":"77","author":"Markert","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.117.078972_bib20","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1124\/dmd.112.046193","article-title":"Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes","volume":"40","author":"M\u00e9nochet","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.078972_bib21","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.20502","article-title":"Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions","volume":"95","author":"Rodgers","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.117.078972_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev-pharmtox-010510-100540","article-title":"Physiologically-based pharmacokinetics in drug development and regulatory science","volume":"51","author":"Rowland","year":"2011","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.117.078972_bib24","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.117.078972_bib25","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1124\/jpet.102.041921","article-title":"Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A","volume":"304","author":"Shitara","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.117.078972_bib26","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1007\/s11095-017-2153-z","volume":"34","author":"Toshimoto","year":"2017","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.117.078972_bib27","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1124\/jpet.103.061614","article-title":"Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat","volume":"308","author":"Treiber","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.117.078972_bib28","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1124\/dmd.106.013615","article-title":"Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil","volume":"35","author":"Treiber","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.078972_bib30","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.3109\/00498259509061925","article-title":"Bosentan, a new endothelin receptor antagonist: prediction of the systemic plasma clearance in man from combined in vivo and in vitro data","volume":"25","author":"Ubeaud","year":"1995","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.117.078972_bib31","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1046\/j.1365-2125.2002.01608.x","article-title":"Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole","volume":"53","author":"van Giersbergen","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.117.078972_bib32","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.clpt.6100075","article-title":"Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects","volume":"81","author":"van Giersbergen","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.117.078972_bib33","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1124\/jpet.114.215970","article-title":"Quantitative prediction of transporter- and enzyme-mediated clinical drug-drug interactions of organic anion-transporting polypeptide 1B1 substrates using a mechanistic net-effect model","volume":"351","author":"Varma","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.117.078972_bib34","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s40262-017-0534-4","article-title":"Target-mediated drug disposition pharmacokinetic-pharmacodynamic model of bosentan and endothelin-1","volume":"56","author":"Volz","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.117.078972_bib35","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1124\/jpet.108.146647","article-title":"Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans","volume":"328","author":"Watanabe","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.117.078972_bib36","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10928-010-9176-y","article-title":"Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans","volume":"37","author":"Watanabe","year":"2010","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1124\/dmd.117.078972_bib37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0009-9236(96)90127-7","article-title":"Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects","volume":"60","author":"Weber","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.117.078972_bib38","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1177\/00912709922008380","article-title":"Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin","volume":"39","author":"Weber","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.117.078972_bib39","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0090-9556(24)15230-0","article-title":"Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects","volume":"27","author":"Weber","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.078972_bib40","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1177\/00912709922008344","article-title":"Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers","volume":"39","author":"Weber","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.117.078972_bib41","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1124\/dmd.116.074823","article-title":"Comparison of methods for estimating unbound intracellular-to-medium concentration ratios in rat and human hepatocytes using statins","volume":"45","author":"Yoshikado","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.078972_bib42","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/cpt.391","article-title":"Quantitative analyses of hepatic OATP-mediated interactions between statins and inhibitors using PBPK modeling with a parameter optimization method","volume":"100","author":"Yoshikado","year":"2016","journal-title":"Clin Pharmacol Ther"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624054953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624054953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.117.078972","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:34:34Z","timestamp":1739903674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624054953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0090955624054953"],"URL":"https:\/\/doi.org\/10.1124\/dmd.117.078972","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physiologically Based Pharmacokinetic Modeling of Bosentan Identifies the Saturable Hepatic Uptake As a Major Contributor to Its Nonlinear Pharmacokinetics","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.117.078972","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}